SNDX vs. AMPH, PTGX, ENTA, DYN, RVMD, SMMT, ELAN, KRYS, OGN, and BBIO
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Protagonist Therapeutics (PTGX), Enanta Pharmaceuticals (ENTA), Dyne Therapeutics (DYN), Revolution Medicines (RVMD), Summit Therapeutics (SMMT), Elanco Animal Health (ELAN), Krystal Biotech (KRYS), Organon & Co. (OGN), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector.
Amphastar Pharmaceuticals (NASDAQ:AMPH) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.
65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Amphastar Pharmaceuticals presently has a consensus target price of $64.67, indicating a potential upside of 52.23%. Syndax Pharmaceuticals has a consensus target price of $34.73, indicating a potential upside of 41.80%. Given Syndax Pharmaceuticals' higher possible upside, research analysts clearly believe Amphastar Pharmaceuticals is more favorable than Syndax Pharmaceuticals.
Amphastar Pharmaceuticals has a net margin of 22.88% compared to Amphastar Pharmaceuticals' net margin of 0.00%. Syndax Pharmaceuticals' return on equity of 29.17% beat Amphastar Pharmaceuticals' return on equity.
Amphastar Pharmaceuticals received 15 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 66.72% of users gave Amphastar Pharmaceuticals an outperform vote while only 64.92% of users gave Syndax Pharmaceuticals an outperform vote.
Amphastar Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 4 articles in the media. Syndax Pharmaceuticals' average media sentiment score of 1.34 beat Amphastar Pharmaceuticals' score of 0.58 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.
Amphastar Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
Summary
Amphastar Pharmaceuticals beats Syndax Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
Free SNDX Stock Alerts